AI assistant
Sending…
LIGAND PHARMACEUTICALS INC — Director's Dealing 2017
Mar 4, 2017
31289_dirs_2017-03-03_41695541-9d24-4b07-9033-263933bc5fb5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2017-03-02
Reporting Person: FOEHR MATTHEW W (President and COO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-03-02 | Common Stock | M | 6879 | $9.97 | Acquired | 97599 | Direct |
| 2017-03-02 | Common Stock | S | 6879 | $103.3891 | Disposed | 90720 | Direct |
| 2017-03-03 | Common Stock | M | 2000 | $9.97 | Acquired | 92720 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-03-02 | Employee Stock Option (right to buy) | $9.97 | M | 6879 | Disposed | 2021-04-18 | Common Stock (6879) | Direct |
| 2017-03-03 | Employee Stock Option (right to buy) | $9.97 | M | 2000 | Disposed | 2021-04-18 | Common Stock (2000) | Direct |
Footnotes
F1: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.
More from LIGAND PHARMACEUTICALS INC
Proxy Solicitation & Information Statement
2026
May 18
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 8
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 1
Major Shareholding Notification
2026
May 1
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 27
Regulatory Filings
2026
Apr 27
Annual Report
2026
Apr 21